éºäŒååææè¡ãããã±ã質æ§é äºæž¬ãèšç®ã¢ã«ãŽãªãºã ãçšããŠãèªç¶çã«ã¯ãªãå šãæ°èŠé åã®ã¿ã³ãã¯è³ªïŒde novoããã±ã質ïŒããã¶ã€ã³ããç¬èªæè¡ãæã€ãã€ãªãã³ãã£ãŒãããå ç«çæ³è¬ãæ°åã³ãããŠã€ã«ã¹ææçCOVID-19ã®æ²»çã»äºé²è¬ã®éçºãè¡ã£ãŠããã
ããŒã ããŒãžïŒhttps://www.neoleukin.com/
èæ¯ãšãã¯ãããžãŒïŒ
ã»ããã±ã質ãã®ãã®ãæ²»çè¬ãšãªã£ãŠããããã±ã質å»è¬åã«ã¯ãã€ã³ã¹ãªã³ããšãªã¹ãããšãã³ãã€ã³ã¿ãŒãã§ãã³ãG-CSFãé µçŽ è£œå€ïŒé µçŽ è£å çæ³ïŒã¢ãã¯ããŒãã«æäœïŒæäœå»è¬åïŒãªã©ãããããããã¯çäœå ã®çç掻æ§ããã±ã質ã ããéºäŒåçµã¿æãæè¡ãçšããŠäœå€ã§è£œé ãããã«æäžãããšãé«ãèšåºå¹æãšäœãæ¯æ§ãšããç¹æ§ãæã€ããšãæãããšãªããå»è¬åãšããŠã®å©çšãé²ããããŠããã
ã»ããçäœå ã«ã¯çŽ10äžçš®é¡ã®ããã±ã質ãçºçŸããŠãããšèããããŠãããããã®äžã§ããã±ã質å»è¬åãšããŠå©çšãããŠããã®ã¯äžèšã®ããã«ããäžéšã§ãããå€ãã®ããã±ã質ã¯åœ¹å²ãåååãã£ãŠããªãã£ããã補é ãå°é£ã ã£ããããã®ã ãããã®ä»ã«ã以äžã®ãããªçç±ãããã
ã»å€©ç¶ããã±ã質ã¯ãã»ãšãã©ã®å Žåãå®å®æ§ãããããã±ã質ã®æ©èœãåªå ããŠé²åããŠããã ãã®çµæãã»ãšãã©ã®å€©ç¶ããã±ã質ã«ã¯æ§é çãªäžèŠåæ§ããããããã¯æº¶è§£æ§ã®äœããçªç¶å€ç°ã®å ç¢æ§ã®äœããªã©ãæ²»çæ³ã®éçºã«èª²é¡ãããããéçæ³çãªç¹æ§ãšãªã£ãŠããããããã®äžèŠåæ§ã¯ã倩ç¶ããã±ã質ã®æ©èœãæãªãããšã¯ãªããã倩ç¶ããã±ã質ãæ²»çè¬ãšããŠåå©çšããããã»ã¹ãèããé»å®³ããå¯èœæ§ãããã
ã»ããã§ãããã±ã質工åŠãçšããã¢ãããŒãã§å»è¬åãšããŠå©çšã§ããããã«æ¹å€ãè¡ãæè¡ãçšããããŠãããäŸãã°ä»¥äžã®ãããªæ¹æ³ã§ããã
ãããã®é¡ç²çã³ãããŒåºæ¿å åïŒG-CSFïŒã®Næ«ç«¯åŽã®5ã¢ããé žã眮æããããšã§ãçç©æŽ»æ§ããã³è¡æŒ¿äžå®å®æ§ã«åªããèªå°äœãã«ãã°ã©ã¹ãã ïŒååå ãã€ã¢ããïŒãéçºãããããŸãéºäŒåçµæãã«ããããã®ãšãªã¹ãããšãã³ïŒEPOïŒãæ¬æ¥æã€3æ¬ã®Nçµååç³éã5æ¬ã«å¢ããããã«ãããšãã³ã¢ã«ãã¡ïŒåååãã¹ãïŒã¯EPOã¬ã»ãã¿ãŒãžã®èŠªåæ§ã¯äœäžãããã®ã®ããšãªã¹ãããšãã³ãšæ¯èŒããŠé·ãäœå åæžæããã³é«ãçç©åŠç掻æ§ã瀺ãããïŒWikipediaããïŒã
ãã以å€ã«ããã©ãªã¢ã«å¯Ÿããããå¹æçãªã¯ã¯ãã³ã®éçºã®ããã®ããã±ã質ã®å®å®å ãã»ãªã¢ãã¯ç ã®æ²»çã®ããã®é µçŽ ã®åŒ·å ãå ç«åæ§ãšãããŒãã®æ瀺ã®ããã®èªå·±çµç¹åããç²å ãå€æ°ã®æäœã®æé©åãªã©ãããã
ã»ãããããã®ã¢ãããŒãã«ã¯éçããããå®å®æ§ãåºæ¬çãªäœçšæ©åºãããã³ããã±ã質é åãªã©ã®æçµè£œåã®çååŠçç¹æ§ã¯ãåºçºç¹ãšããŠäœ¿çšãããããã±ã質ã«æ¬è³ªçã«çµã³ã€ããŠãããããã«ã倩ç¶ã®ããã±ã質ã¯ãäžå®å®ã«ãªã£ãããæ©èœããªããªã£ããããåã«ãéãããæ°ã®æ¹å€ã«ããèããããªãããšãããããããã®çµæã倩ç¶ããã±ã質ããéçºãããæ²»ççšããã±ã質ã¯ããã°ãã°å®å®æ§ã補é æ§ã«å£ããå€ãã®å Žåãçç掻æ§ãèããäœäžããã
ã»ããã§å šãæ°ãã人工ã®æŽ»æ§ããã±ã質ãçã¿åºãæè¡ãšããŠãde novoããã±ã質ãã¶ã€ã³æè¡ãéçºãããŠããŠãããde novoããã±ã質ãã¶ã€ã³ã¯ãèšç®ã¢ã«ãŽãªãºã ãçšããŠããã±ã質ãäœæããæè¡ã§ãèªç¶ã®é²åã«ãã£ãŠã§ããããã±ã質é åãããææ°é¢æ°çã«å€§ããªããã±ã質é å空éã«ã¢ã¯ã»ã¹ããããšãã§ãããäŸãã°ã100æ®åºã®ããã±ã質ãèããå Žåã20åã®å€©ç¶ã¢ããé žããã¹ãŠçµã¿åãããé åã®å¯èœæ°ã¯çŽ10ã®123ä¹åãããããèªç¶ã®é²åãããã±ã質工åŠã«ãã£ãŠæ¡åãããããã±ã質ã®ç·æ°ã¯ã10ã®20ä¹çš®é¡ã®é åã®ãªãŒããŒãšæšå®ãããŠããããã®ãã倩ç¶ã®ããã±ã質ã§ã¯æºããããŠããªã課é¡ã解決ããããšãæåŸ ãããã
ã»de novoããã±ã質ãã¶ã€ã³ã¯ èšç®èœåãéºäŒååææè¡ãããã±ã質æ§é äºæž¬ãèšç®ã¢ã«ãŽãªãºã ã®é²æ©ã®çµã¿åããã«ãã£ãŠå¯èœãšãªã£ããå¹ åºã圢ç¶ãšå€§ãããæã€å€æ°ã®de novoããã±ãè³ªè¶³å ŽïŒããªãã¡ãæ©èœãæããªããããæãç³ãŸããããã±ã質æ§é ïŒãèšèšãããæ©èœæ§ååã®éçºã®åºçºç¹ãšãªã£ããäŸãã°ãäžæŽ»æ§ãªde novoããã±ã質ã®è¶³å Žã«ãæ©èœçãªïŒæŽ»æ§ãæã€ïŒã¢ããŒããå°å ¥ããããšïŒã¢ããŒãã°ã©ãããšããŠç¥ãããŠããïŒã«ãããããã±ã質èšèšè ã¯ããã€ãã®æ©èœçãªïŒæŽ»æ§ãæã€ïŒde novoããã±ã質ãäœæããããšãã§ããããã«ãªã£ãããã®äŸãšããŠã¯ãã€ã³ãã«ãšã³ã¶ããããªãã¹ç¥çµæ¯ã«å¯Ÿããæ²»çã®å¯èœæ§ãæã€äœåãã®é«èŠªåæ§ããããã±ã質ããã«ã¹ã¿ãã€ãºå¯èœãªçŽ°èæ©èœãæã€çç掻æ§ããã±ã質ã¹ã€ãããªã©ãæããããã
ã»ããäžã€ã®ããã±ã質èšèšã¢ãããŒãã¯ãç®çã®æ©èœãéæããããã«æ§æ³æ®µéãã調æŽãããæ©èœçãªde novoããã±ã質ãäœæããæ¹æ³ã§ããããã®ãããªãæå³çã«æ©èœãããde novoããã±ã質ã®èšèšã«ã¯ãæçµçãªèšèšã®åœ¢ç¶ããµã€ãºãããã³æ©èœãé«åºŠã«å¶åŸ¡ããå¿ èŠãããïŒãŸããç®çãšããæ©èœéšäœã®æ§é ã«é¢ããäºåã®ç¥èãä»®å®ãå¿ èŠãšããïŒããã®äŸãšããŠã¯ããšãã¹ã¿ã€ã³ããŒãŠã€ã«ã¹ããã±ã質é»å®³å€ã®èšèšãè貫éåZn2+茞éãããç¶ããã±ã質ãªã©ãããã
ã»de novoããã±ã質ã¯ã䞊å€ããå ç¢æ§ã瀺ããçãæ§é åãããé£çµã«ãŒããæã€èŠåçãªäºæ¬¡æ§é èŠçŽ ãååã«å å¡«ãããçæ°Žæ§ã³ã¢ã倧éšåã極æ§ãæã€é²åºè¡šé¢ãããã³éåžžã«æºè¶³åºŠã®é«ã極æ§çžäºäœçšãªã©ãçæ³åãããããã±ã質æ§é ã®ååã«åŸãããã«èšèšããããšãã§ãããããde novoããã±ã質ã¯å€©ç¶ããã±ã質ãæã€å¶éã®å€ããå æããããšãã§ããŠãããããã«ãçŸåšã®ããã±ã質èšèšæ³ã¯ãååå çžäºäœçšïŒç¹ã«é£ç¶ããæ®åºéïŒã匷ãååãäœãããšã«åªããŠããããã®çµæã倩ç¶ã®ããã±ã質ãšæ¯èŒããŠéåžžã«é«ãæ¬è³ªçå®å®æ§ãšæãç³ã¿æ§ãæã€de novoããã±ã質ãèªçããããšãå¢å ããŠããŠããããã®çµæãçæ³åãããæ§é ãæã€de novoããã±ã質ã¯ã極端ãªèç±æ§ãçªç¶å€ç°ã®é å¥æ§ãªã©ã®çååŠçç¹æ§ã瀺ãããã«ãªã£ãããã以å€ã«ãde novoããã±ã質ãã¶ã€ã³ã¯ã補é æ§ã溶解æ§ãããã³èª¿æŽå¯èœæ§ãªã©ã®éåžžã«æãŸããçååŠçç¹æ§ãæããæ²»ççšããã±ã質ã®åµè£œãå¯èœã«ããããšãã§ããã
ã»ä»å玹ä»ããNeoleukin Therapeuticsã¯ãã®de novoããã±ã質ãã¶ã€ã³ãçšããŠãããå ç«æ²»çè¬ã®éçºãè¡ã£ãŠãããã€ãªãã³ãã£ãŒã§ããããªãŒããããã¯ãã§ããNL-201ã¯ã€ã³ã¿ãŒãã€ãã³-2ïŒIL-2ïŒãšã€ã³ã¿ãŒãã€ãã³-15ïŒIL-15ïŒã®äž¡æ¹ã®æ©èœãæš¡å£ããde novoããã±ã質ãçšããå ç«çæ³ã§ããã
ãã€ãã©ã€ã³ïŒ
ã»NL-201
ã€ã³ã¿ãŒãã€ãã³-2ïŒIL-2ïŒãšã€ã³ã¿ãŒãã€ãã³-15ïŒIL-15ïŒã®äž¡æ¹ã®æ©èœãæš¡å£ããde novoããã±ã質ã
IL-2ã¯åŒ·åãªå ç«åºæ¿æ§ãµã€ãã«ã€ã³ãçµæãIL-2ïŒã¢ã«ãã¹ãã€ãã³ïŒã¯ãããæ²»çã«äœ¿çšãããŠãããããã®æ¯æ§ã®ããèšåºå¿çšã¯éåžžã«éå®çã ã£ããçäœå ã§ã¯ãIL-2ã®å¹æã¯ãã¢ã«ãã¡ïŒCD-25ïŒãããŒã¿ïŒCD122ïŒãã¬ã³ãïŒCD132ïŒã®3ã€ã®éšåãããªãå容äœãšã®çžäºäœçšã«ãã£ãŠåªä»ããããIL-2ã®æ¯æ§ã¯ãCD25ãšã®çžäºäœçšã«ãã£ãŠæªåãããNL-201ã¯ãCD25ã«çµåããããšãªãIL-2ã®ã·ã°ãã«äŒéã匷åã«åºæ¿ããããã±ã質ã§ãIL-2å容äœã®Î²éããã³Î³éãšæä»çã«çžäºäœçšããæè «çå¹æã®ããT现èãéžæçã«å¢æ®ãããããŸããIL-15ã¯IL-2ãšåãβã»Î³éãå ±æããŠãããããNL-201ã¯IL-15ã®æŽ»æ§ããã«ã«çºæ®ããæè «çNK现èãåæã«å¢æ®ãããããšãã§ããïŒåèïŒãåå€ã§ã®äœ¿çšãä»ã®ããå ç«æ²»çè¬ãšã®äœµçšä»¥å€ã«ããä»å®¶çŽ°èçæ³ãšã®äœµçšã«ããã移æ€ãããCAR-T现èãNK现èã®å¢æ®ã»ç¶æãæåŸ ãããã
éçºäžã®é©å¿ç
ã»åèšåºç 究段é
ãã
ã»NL-CVX1
SARS-CoV-2ã¹ãã€ã¯ããã±ã質ã®ã®å容äœçµåãã¡ã€ã³ã«çµåããããã¢ã³ãžãªãã³ã·ã³å€æé µçŽ 2ïŒhACE2ïŒãšã¹ãã€ã¯ããã±ã質ã®çµåãé»å®³ããããã«ç¹ç°çã«èšèšãããde novoããã±ã質ãã³ã€ãNL-CVX1ãäºé²çã«çµéŒ»ååæäžãããšãããèŽæ»éã®SARS-CoV-2ã«ææãããã ã¹ã¿ãŒã¯ãã¹ãŠçåããïŒåèïŒã
éçºäžã®é©å¿ç
ã»éçºã¹ããŒãžäžæ
æ°åã³ãããŠã€ã«ã¹ææçCOVID-19ã®æ²»çè¬ããã³äºé²è¬
ã»de novoãµã€ãã«ã€ã³å容äœã¢ãŽãã¹ãããã³ã¢ã³ã¿ãŽãã¹ãã®èšèš
ãµã€ãã«ã€ã³å容äœã¢ãŽãã¹ãïŒããå ç«çæ³è¬ãšããŠïŒ
ãµã€ãã«ã€ã³å容äœã·ã°ãã«ã®ãã©ã³ã¹ãå埩ãããããšãå¯èœã«ãããde novoãµã€ãã«ã€ã³æš¡å£è¬ïŒèªå·±å ç«çŸæ£ãã¢ã¬ã«ã®ãŒçŸæ£æ¹åè¬ãšããŠïŒ
ã³ã¡ã³ãïŒ
ã»ããã±ã質æ§é çç©åŠãšèšç®ç§åŠãçšããŠåæçç©åŠçã¢ãããŒãã§ãå šãæ°ãã人工ããã±ã質ãäœãåºãã¢ãããŒãã¯ããããã©ãã©ãåµè¬ã«å¿çšãããŠããå¯èœæ§ãé«ãã®ã§ã¯ãšæããããçäœå ã§ããã±ã質åæã«äœ¿ãããŠããã¢ããé žã¯20çš®é¡ã ããæ°ããªæè¡ãšããŠé倩ç¶ã¢ããé žãçµã¿èŸŒãã ããã±ã質åææè¡ãéçºãããŠããŠããããããã®äžããå šãæ°ããè¬çäœçšãæã€ããã±ã質å»è¬åãçãŸããŠããå¯èœæ§ãããïŒåèïŒã4å¡©åºã³ãã³ãçšããde novoããã±ã質åæãªã©ãåæçç©åŠã¢ãããŒãã®ä»åŸã®å±éã«ã泚ç®ã
ããŒã¯ãŒãïŒ
ã»åæçç©åŠ
ã»de novoããã±ã質
ã»ããå ç«çæ³
ã»æ°åã³ãããŠã€ã«ã¹ææçCOVID-19
å 責äºé ïŒ
æ£ç¢ºãªæ å ±æäŸãå¿ãããŠããŸãããæ¬å 容ã«åºã¥ããåŠäœãªãã¢ã¯ã·ã§ã³ã«å¯ŸããŠãã±ã³ã¯è²¬ä»»ããšããŸããããããããé¡ãããŸãã